1288 related articles for article (PubMed ID: 33249194)
21. Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder.
Rouanne M; Bajorin DF; Hannan R; Galsky MD; Williams SB; Necchi A; Sharma P; Powles T
Eur Urol Oncol; 2020 Dec; 3(6):728-738. PubMed ID: 33177001
[TBL] [Abstract][Full Text] [Related]
22. Genetically driven CD39 expression shapes human tumor-infiltrating CD8
Gallerano D; Ciminati S; Grimaldi A; Piconese S; Cammarata I; Focaccetti C; Pacella I; Accapezzato D; Lancellotti F; Sacco L; Caronna R; Melaiu O; Fruci D; D'Oria V; Manzi E; Sagnotta A; Parrino C; Coletta D; Peruzzi G; Terenzi V; Battisti A; Cassoni A; Fadda MT; Brozzetti S; Fazzi K; Grazi GL; Valentini V; Chirletti P; Polimeni A; Barnaba V; Timperi E
Int J Cancer; 2020 Nov; 147(9):2597-2610. PubMed ID: 32483858
[TBL] [Abstract][Full Text] [Related]
23. Targeting PD-1 and Tim-3 Pathways to Reverse CD8 T-Cell Exhaustion and Enhance Ex Vivo T-Cell Responses to Autologous Dendritic/Tumor Vaccines.
Liu J; Zhang S; Hu Y; Yang Z; Li J; Liu X; Deng L; Wang Y; Zhang X; Jiang T; Lu X
J Immunother; 2016 May; 39(4):171-80. PubMed ID: 27070448
[TBL] [Abstract][Full Text] [Related]
24. PD-1 blockade therapy promotes infiltration of tumor-attacking exhausted T cell clonotypes.
Nagasaki J; Inozume T; Sax N; Ariyasu R; Ishikawa M; Yamashita K; Kawazu M; Ueno T; Irie T; Tanji E; Morinaga T; Honobe A; Ohnuma T; Yoshino M; Iwata T; Kawase K; Sasaki K; Hanazawa T; Kochin V; Kawamura T; Matsue H; Hino M; Mano H; Suzuki Y; Nishikawa H; Togashi Y
Cell Rep; 2022 Feb; 38(5):110331. PubMed ID: 35108529
[TBL] [Abstract][Full Text] [Related]
25. Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer.
Sugie T; Sato E; Miyashita M; Yamaguchi R; Sakatani T; Kozuka Y; Moritani S; Suzuki E; Kakimi K; Mikami Y; Moriya T
Breast Cancer; 2020 Jul; 27(4):519-526. PubMed ID: 32447649
[TBL] [Abstract][Full Text] [Related]
26. High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer.
Mollavelioglu B; Cetin Aktas E; Cabioglu N; Abbasov A; Onder S; Emiroglu S; Tükenmez M; Muslumanoglu M; Igci A; Deniz G; Ozmen V
World J Surg Oncol; 2022 Oct; 20(1):349. PubMed ID: 36271406
[TBL] [Abstract][Full Text] [Related]
27. Squamous cell carcinomas escape immune surveillance via inducing chronic activation and exhaustion of CD8+ T Cells co-expressing PD-1 and LAG-3 inhibitory receptors.
Mishra AK; Kadoishi T; Wang X; Driver E; Chen Z; Wang XJ; Wang JH
Oncotarget; 2016 Dec; 7(49):81341-81356. PubMed ID: 27835902
[TBL] [Abstract][Full Text] [Related]
28. Functional Heterogeneity of CD4
Oja AE; Piet B; van der Zwan D; Blaauwgeers H; Mensink M; de Kivit S; Borst J; Nolte MA; van Lier RAW; Stark R; Hombrink P
Front Immunol; 2018; 9():2654. PubMed ID: 30505306
[TBL] [Abstract][Full Text] [Related]
29. CD8
Dumont C; Jacquier A; Verine J; Noel F; Goujon A; Wu CL; Hung TM; Desgrandchamps F; Culine S; Carosella ED; Rouas-Freiss N; LeMaoult J
Cancer Immunol Res; 2019 Oct; 7(10):1619-1632. PubMed ID: 31451484
[TBL] [Abstract][Full Text] [Related]
30. PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8
Whelan S; Ophir E; Kotturi MF; Levy O; Ganguly S; Leung L; Vaknin I; Kumar S; Dassa L; Hansen K; Bernados D; Murter B; Soni A; Taube JM; Fader AN; Wang TL; Shih IM; White M; Pardoll DM; Liang SC
Cancer Immunol Res; 2019 Feb; 7(2):257-268. PubMed ID: 30659054
[TBL] [Abstract][Full Text] [Related]
31. PD-1 blockade combined with IL-33 enhances the antitumor immune response in a type-1 lymphocyte-mediated manner.
He H; Shi L; Meng D; Zhou H; Ma J; Wu Y; Wu Y; Gu Y; Xie W; Zhang J; Zhu Y
Cancer Treat Res Commun; 2021; 28():100379. PubMed ID: 33951555
[TBL] [Abstract][Full Text] [Related]
32. Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1
Kurtulus S; Madi A; Escobar G; Klapholz M; Nyman J; Christian E; Pawlak M; Dionne D; Xia J; Rozenblatt-Rosen O; Kuchroo VK; Regev A; Anderson AC
Immunity; 2019 Jan; 50(1):181-194.e6. PubMed ID: 30635236
[TBL] [Abstract][Full Text] [Related]
33. CD103+ Tumor Infiltrating Lymphocytes Predict a Favorable Prognosis in Urothelial Cell Carcinoma of the Bladder.
Wang B; Wu S; Zeng H; Liu Z; Dong W; He W; Chen X; Dong X; Zheng L; Lin T; Huang J
J Urol; 2015 Aug; 194(2):556-62. PubMed ID: 25752441
[TBL] [Abstract][Full Text] [Related]
34. Programmed death ligand-1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder.
Wang B; Pan W; Yang M; Yang W; He W; Chen X; Bi J; Jiang N; Huang J; Lin T
Cancer Sci; 2019 Feb; 110(2):489-498. PubMed ID: 30548363
[TBL] [Abstract][Full Text] [Related]
35. Transcriptome Profiling Identifies TIGIT as a Marker of T-Cell Exhaustion in Liver Cancer.
Ostroumov D; Duong S; Wingerath J; Woller N; Manns MP; Timrott K; Kleine M; Ramackers W; Roessler S; Nahnsen S; Czemmel S; Dittrich-Breiholz O; Eggert T; Kühnel F; Wirth TC
Hepatology; 2021 Apr; 73(4):1399-1418. PubMed ID: 32716559
[TBL] [Abstract][Full Text] [Related]
36. PD-1+ Tim3+ tumor-infiltrating CD8 T cells sustain the potential for IFN-γ production, but lose cytotoxic activity in ovarian cancer.
Sawada M; Goto K; Morimoto-Okazawa A; Haruna M; Yamamoto K; Yamamoto Y; Nakagawa S; Hiramatsu K; Matsuzaki S; Kobayashi E; Kawashima A; Hirata M; Iwahori K; Kimura T; Ueda Y; Kimura T; Wada H
Int Immunol; 2020 May; 32(6):397-405. PubMed ID: 32009163
[TBL] [Abstract][Full Text] [Related]
37. Dickkopf 1 impairs the tumor response to PD-1 blockade by inactivating CD8+ T cells in deficient mismatch repair colorectal cancer.
Sui Q; Liu D; Jiang W; Tang J; Kong L; Han K; Liao L; Li Y; Ou Q; Xiao B; Liu G; Ling Y; Chen J; Liu Z; Zuo Z; Pan Z; Zhou P; Zheng J; Ding PR
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33782107
[TBL] [Abstract][Full Text] [Related]
38. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
39. TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8
Seo H; Chen J; González-Avalos E; Samaniego-Castruita D; Das A; Wang YH; López-Moyado IF; Georges RO; Zhang W; Onodera A; Wu CJ; Lu LF; Hogan PG; Bhandoola A; Rao A
Proc Natl Acad Sci U S A; 2019 Jun; 116(25):12410-12415. PubMed ID: 31152140
[TBL] [Abstract][Full Text] [Related]
40. Exploratory analysis of immune checkpoint receptor expression by circulating T cells and tumor specimens in patients receiving neo-adjuvant chemotherapy for operable breast cancer.
Wesolowski R; Stiff A; Quiroga D; McQuinn C; Li Z; Nitta H; Savardekar H; Benner B; Ramaswamy B; Lustberg M; Layman RM; Macrae E; Kassem M; Williams N; Sardesai S; VanDeusen J; Stover D; Cherian M; Mace TA; Yu L; Duggan M; Carson WE
BMC Cancer; 2020 May; 20(1):445. PubMed ID: 32429929
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
